Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy
- 30 November 2014
- journal article
- review article
- Published by Taylor & Francis in CNS Oncology
- Vol. 3 (6) , 407-419
Abstract
Glioma are the most common supra-tentorial brain tumor in the USA with an estimated annual incidence of 17,000 new cases per year. Dynamic susceptibility-weighted contrast-enhanced (DSC) perfusion MRI noninvasively characterizes tumor biology allowing for the diagnosis and therapeutic monitoring of glioma. This MRI technique utilizes the rapid changes in signal intensity caused by a rapid intravascular bolus of paramagnetic contrast agent to calculate physiologic perfusion metrics. DSC perfusion MRI has increasingly become an integrated part of glioma imaging. The specific aim of this article is to review the benefits of DSC perfusion MRI in the therapy of glioma.Keywords
Funding Information
- the NIH (5T32EB001631-07)
This publication has 59 references indexed in Scilit:
- Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastomaNeuro-Oncology, 2012
- EGFRvIII Antibody–Conjugated Iron Oxide Nanoparticles for Magnetic Resonance Imaging–Guided Convection-Enhanced Delivery and Targeted Therapy of GlioblastomaCancer Research, 2010
- Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histologyNeuro-Oncology, 2010
- Glioblastoma Multiforme Regional Genetic and Cellular Expression Patterns: Influence on Anatomic and Physiologic MR ImagingRadiology, 2010
- Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR ImagingRadiology, 2009
- EGFRvIII‐Targeted Vaccination Therapy of Malignant GliomaBrain Pathology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumoursNeuroradiology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005